Ocular Therapeutix officer proposes $232K share sale
Morgan Stanley Smith Barney LLC Executive Financial Services is named as broker, with NASDAQ shown as the market for the proposed sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ocular Therapeutix, Inc. officer Namrata Saroj reported a proposed sale of 35,370 common shares, with an approximate sale date of November 5, 2026. The notice lists an aggregate market value of $231,836.20 and identifies restricted stock vesting under a registered plan on November 4, 2026, as the source of the shares.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Vesting Under a Registered Plan financial
registered plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.